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Abstract. dl-Ethylketazocine (EKC, 0.01 mg/kg) and saline 
were established as discriminative stimuli for food-main- 
tained responding in macaque monkeys. Thirty consecutive 
presses on a right or left lever were reinforced with food, 
contingent on whether EKC or saline were administered 
before the session. For tests of antagonism, naltrexone, or 
UM 979 [(/)-5,9-alpha-dimethyl-2-(3-furylmethyl)-2'-hy- 
droxy-6,7-benzomorphan] was administered concomitantly 
with EKC, dl-cyclazocine, or nalorphine. Both antagonists 
blocked completely the EKC discriminative stimulus. The 
antagonism of the stimulus and rate-altering effects of EKC 
was surmountable, with considerable intersubject variabil- 
ity in the magnitude of the EKC dose increase required to 
overcome the blockade. Cyclazocine and nalophine, mixed 
agonist-antagonist opioids that share stimulus properties 
with EKC, were also susceptible to antagonism. Naltrexone 
antagonized completely the EKC stimulus effects of 
nalorphine; naltrexone and UM 979 antagonized com- 
pletely the EKC stimulus effects of cyclazocine. Naltrexone 
antagonism of the cyclazocine stimulus was not surmount- 
able, due to a lack of antagonism of the rate-decreasing 
effects of high cyclazocine doses. 
Key words: Drug discrimination - x opioids - Ethylke- 
tazocine - Cyclazocine - Nalorphine - Naltrexone - 
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Drug discrimination studies have demonstrated consider- 
able overlap among the stimulus properties of putative 
opioids (Herling and Woods 1981; Holtzman 1982; Tang 
and Code 1983; Young et al. 1984). The reference stimuli 
d/-ethylketazocine (EKC) and nalorphine generally display 
symmetrical discriminative effects in macaques and rats, 
sharing stimulus properties with each other and a range of 
other x opioids, including dl-cyclazocine (Hein et al. 1981; 
Hirschhorn 1977; Shearman and Herz 1982; Tang and Code 
1983; Young et al. 1984). The reference stimulus d/-cycla- 
zocine, explored primarily in rats and squirrel monkeys, 
also shares stimulus properties with many putative 
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opioids, as well as an additional group of phencyclidine-like 
drugs (Herling and Woods 1981; Holtzman 1982 for 
reviews). 
One dimension along which these stimuli may differ is 
their susceptibility to opioid antagonists. An EKC training 
stimulus is antagonized completely by naltrexone, nalox- 
one, and the benzomorphan antagonist MR 2266 in 
macaques and rats (Hein et al. 1981; Herling and Shannon 
1982; Shearman and Herz 1982); a nalorphine training 
stimulus is blocked by naloxone in macaques (Tang and 
Code 1983). A cyclazocine training stimulus, in contrast, is 
antagonized completely by naltrexone or naloxone in 
squirrel monkeys (Schaefer and Holtzman 1978; Teal and 
Holtzman 1980b, c), but is not readily antagonized in rats 
(Teal and Holtzman 1980a). Additionally, the cyclazo- 
cine-like stimuli produced by certain other mixed agon- 
ist-antagonist opioids are not sensitive to naloxone or 
naltrexone antagonism (Schaefer and Holtzman 1978; Teal 
and Holtzman 1980b). 
The present experiment further compared the ability of 
opioid antagonists to block the discriminative effects of 
EKC, nalorphine, and cyclazocine in macaques trained to 
discriminate a single agent (EKC). Experiments assessed 
both the ability of naltrexone to block discriminably similar 
doses of each drug, and also the ability of EKC and 
cyclazocine to surmount such antagonism. Additionally, 
since previous workers have suggested that benzomorphan 
derivatives may be selective antagonists of • opioids 
(Roemer et al. 1980; Shearman and Herz 1982), the ability 
of the representative benzomorphan UM 979 to antagonize 
the stimulus effects of EKC and cyclazocine was 
assessed. 
Materials and methods 
One male rhesus macaque (Macaca mulatta, 975) and two 
male pigtail macaques (Macaca nemestrina; 1204, 1205) 
served as subjects. Each monkey had a history of 
lever-press responding maintained by food or IV drug 
injections and had received opioids and various other 
behaviorally active drugs in previous studies. Monkey 975 
had participated in a previous study of the EKC stimulus 
(Hein et al. 1981). All monkeys were maintained at 
approximately 85% of their free-feeding weights 
(7.5-9.0 kg) by Purina Monkey Chow delivered after each 
session and at midday on weekends. Dietary supplements 
included vitamins every day and flesh fruit when available. 
Each monkey was given 40 mg isoniazid on a sugar cube 
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each day and was tested for tuberculosis every 6 months. 
The monkeys were housed in individual primate cages with 
water freely available. 
Experiments were conducted in enclosed ventilated 
chambers, as described by Hein et al. (1981). Each chamber 
was equipped with two response levers, an externally 
mounted pellet dispenser, and a receptacle for 300 mg 
banana-flavored food pellets (Noyes, Formula G, Lancas- 
ter, NH). Lights of various colors were mounted at the top 
of the front wall of the chambers. Experiments were 
controlled and data collected by a Texas Instruments 960A 
computer located in an adjacent room. 
EKC (0.01 mg/kg IM) and saline were established as 
discriminative stimuli for food-maintained responding by 
the method described by Hein et al. (1981). Before each 
training session, the subject was placed in a primate chair, 
injected with EKC or saline, and placed in the experimental 
chamber. After a 10-min pretreatment interval, a light was 
illuminated to signal the start of the session. The light 
remained on until the end of the session, except for the 
brief time of each pellet delivery. Following EKC admin- 
istration, responses on only one of the two levers produced 
food delivery; following saline administration, responses on 
the other lever produced food delivery. The response 
requirement was gradually increased over successive ses- 
sions until 20 consecutive responses on the correct lever 
were required for food delivery. Responses on the incorrect 
lever reset the response requirement on the correct lever. 
Sessions ended after 75 pellet deliveries or 1 h, whichever 
occurred first. 
EKC and saline administration alternated daily during 
training. Training continued until two criteria were met for 
nine consecutive sessions: The total number of responses 
emitted before the first pellet delivery was less than 40, and 
at least 90% of the total session responses were emitted on 
the appropriate lever. Training sessions were conducted 6 
days/week. 
Once the above criteria were met, saline, and various 
doses of EKC, nalorphine, cyclazocine, naltrexone, and 
UM 979, alone and in combination, were examined for 
their capacity to cause drug-appropriate responses. Test 
sessions were identical to training sessions, except that the 
pretreatment time was extended to 20rain, and 20 
consecutive responses on either lever were reinforced. Test 
days alternated with training days to ensure that the 
discrimination remained intact. If a subject failed to meet 
the performance criteria on a training day, further testing 
was deferred until 2 consecutive days of acceptable 
performance had occurred. 
Initially, dose-effect curves were generated for EKC, 
cyclazocine, and nalorphine. The doses tested covered a 
range from a dose that evoked saline-appropriate responses 
to doses that evoked predominantly drug-appropriate 
responses or markedly reduced response rates. Naltrexone 
and UM 979 were then tested alone at doses of 
0.01-1.0 mg/kg. For antagonism tests, a dose of EKC 
(0.01mg/kg), cyclazocine (0.03mg/kg), or nalorphine 
(0.32mg/kg) that produced complete EKC-appropriate 
responding was administered concomitantly with selected 
doses of naltrexone or UM 979. For tests of surmountable 
antagonism, effective doses of naltrexone were given 
concomitantly with a range of EKC and cyclazocine doses, 
and effective doses of UM 979 were given concomitantly 
with a range of EKC doses. 
Data are presented as two functions of dose. First, the 
number of responses emitted on the lever appropriate to 
the EKC training dose is expressed as a percentage of the 
total number of responses emitted during the session. 
Second, the overall rate of responding on the two levers is 
presented as a percentage of the average rate for the saline 
training sessions conducted during the period of each 
antagonism study. The distribution of responses on the two 
levers was not evaluated if fewer than 100 responses were 
emitted during the session. 
The following compounds were used: d/-cyclazocine 
base and d/-ethylketazocine methane sulfonate (gifts of Dr. 
W. Michne, Sterling-Winthrop Research Institute, Rensse- 
laer, NY), nalorphine hydrochloride (obtained from Eli 
Lilly and Company, Indianapolis, IN), naltrexone hydro- 
chloride (gift of Endo Laboratories, Garden City, NY), and 
UM 979 [MR 1452; (l)-5,9-alpha-dimethyl-2-(3-furyl- 
methyl)-2'-hydroxy-6,7-benzomorphan methane sulfonate; 
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Fig, 1. Effects of graded doses of naltrexone or UM 979 in 
combination with 0.01 mg/kg ethylketazocine (EKC) in individual 
macaque monkeys for which 0.01 mg/kg EKC and saline served as 
discriminative stimuli for food-reinforced responses. Upper panel 
ordinates: number of responses emitted on the EKC-appropriate 
lever, expressed as a percentage of the total session responses. 
Lower panel ordinates: rate of responding during the session, 
expressed as a percentage of the mean response rates during saline 
training sessions. Abscissae, mg/kg doses of naltrexone (left 
panels) or UM 979 (right panels) administered concomitantly with 
0.01 mg/kg EKC. Each drug combination data point represents a 
single determination in each subject. Points at E represent tests 
20 min after concomitant administration of 0.01 mg/kg EKC and 
saline. Points at C in the upper panels represent the average 
percentage of responses emitted on the EKC-appropriate lever 
during training sessions that preceded test sessions. Points at C in 
the lower panels present the effects of 0.01 mg/kg EKC on rate of 
responding during training sessions. The symbol and average 
response rates (responses/s) during saline training sessions for each 
monkey are as follows: 975 D, 1.86; 1205 I ,  1.92; 1204 I~, 
2.22 
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gift of Dr. H. Merz, Boehringer Ingelheim, Federal 
Republic of Germany). 
EKC and cyclazocine were dissolved in sterile water to 
which a small amount of lactic acid was added. Sodium 
hydroxide was used to adjust the pH of the solutions to 
above pH 4. Nalorphine, naltrexone, and UM 979 were 
dissolved in 0.9% saline. Doses of all drugs are expressed as 
the forms given above. Solutions were prepared to deliver 
each mg/kg injection dose in 0.1-1.5 ml. Injections were 
made into the thigh muscle; when drug combinations were 
studied, each injection was made into a different leg. 
R e s u l t s  
Discriminative control by 0.01 mg/kg EKC and saline was 
achieved in 86 or 109 sessions in the two new monkeys 1205 
and 1204. During test sessions, an EKC dose of 0.001 mg/kg 
evoked only saline-appropriate responses; higher doses 
(0.003 or 0.01-0.03 mg/kg) evoked primarily drug-appro- 
priate responses. Naltrexone or UM 979 doses ot 
0 .01-1 .0mg/kg produced only saline-appropriate res- 
ponses and generally did not alter the response rates usually 
emitted in the presence of saline (data not shown). In 
monkey 1205, however, 1.0 mg/kg UM 979 completely 
abolished responding throughout the 1-h experimental 
session. Lower doses of UM 979 did not decrease response 
rates in this subject. 
Naltrexone and UM 979 blocked the EKC stimulus in a 
dose-dependent fashion (Fig. 1, upper panels). Complete 
antagonism of the EKC stimulus was achieved with 
naltrexone doses of 0.03 or 0.1 mg/kg and with UM 979 
doses of 0.1, 0.32, or 0.56 mg/kg. The antagonists also 
blocked the rate-altering effects of EKC (Fig. 1, lower 
panels). During the period of EKC-naltrexone combina- 
tions, EKC decreased response rates in monkeys 1204 and 
1205 and increased rates in monkey 975. Naltrexone 
blocked both effects, generally at doses that also blocked 
the EKC stimulus. During the period of EKC-UM 979 
combinations, EKC decreased response rates in all mon- 
keys. For monkeys 975 and 1204, UM 979 blocked these 
rate decreases at doses of 0.01 mg/kg and above. For 
monkey 1205, no UM 979 dose completely blocked the 
rate-decreasing effects of EKC, and the combination of  
1.0 mg/kg UM 979 and 0.01 mg/kg EKC eliminated res- 
ponding throughout the 1-h sess ion.  
Both naltrexone and UM 979 exerted a surmountable 
antagonism of the stimulus and rate-decreasing effects of 
EKC (Figs. 2 and 3). There was considerable intersubject 
variability in the magnitude of the EKC dose increase 
required to overcome naltrexone or UM 979 antagonism. 
The dose of EKC required for discriminative control was 
increased 3-56-fold in the presence of 0.1 mg/kg naltrex- 
one, and was increased 18-560-fold in the presence of 
1.0 mg/kg naltrexone. The dose of EKC required for 
discriminative control was increased 3-10-fold in the 
presence of 0.32 or 1.0 mg/kg UM 979. In general, smaller 
increases in EKC dose were required to surmount anta- 
gonism of its rate-decreasing effects. Comparison of the 
two antagonists showed that the lowest effective dose of 
each produced equivalent antagonism of the EKC stimulus 
in the two monkeys tested with both combinations. 
Equivalent increases in EKC dose were required to 
overcome the effects of 0.10mg/kg naltrexone and 
0.32 mg/kg UM 979 in monkeys 975 and 1204. 
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Fig. 2. Ethylketazocine (EKC) dose-response curves determined alone (O) or in combination with graded doses of naltrexone 
(O 0.10 mg/kg; [] 0.32 mg/kg; tl) 1.0 mg/kg) in three macaques for which 0.01 mg/kg EKC and saline served as discriminative stimuli for 
food-reinforced responses. Upperpanel ordinates: number of responses emitted on the EKC-appropriate lever, expressed as a percentage 
of the total session responses. Lower panel ordinates: rate of responding during the session, expressed as a percentage of the mean 
response rate during saline training sessions. Abscissae: mg/kg dose of EKC. Each point represenB a single determination in each subject. 
Points at S represent tests after saline administered alone or in combination with each dose of the antagonist. Average response rates 
(responses/s) for individual monkeys during saline training sessions were: 975, 1.71; 1205, 1.92; 1204, 2.20 
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Fig. 3. Ethylketazocine (EKC) dose-response curves determined 
alone (O) or in combination with graded doses of UM 979 (R 
0.32 mg/kg; tD 1.0 mg/kg) in two macaques for which 0.01 mg/kg 
EKC and saline served as discriminative stimuli for food-rein- 
forced responses. Average response rates (responses/s) for 
individual monkeys during saline training sessions were: 975, 1.71; 
1204, 2.08. Other details as in Fig. 2 
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The mixed agonist-antagonists cyclazocine and nalor- 
phine exerted EKC-like stimulus effects that were also 
susceptible to antagonism by naltrexone or UM 979 (Fig. 
4). Naltrexone and UM 979 were tested in combination 
with the lowest dose of cyclazocine (0.03 mg/kg) required to 
evoke complete EKC-appropriate responses in all mon- 
keys. A naltrexone dose of 0.32mg/kg blocked the 
cyclazocine stimulus in all three monkeys; certain naltrex- 
one doses blocked the rate decreases produced by cycla- 
zocin.e in two monkeys. UM 979 (0.32 or 0.56 mg/kg) also 
blocked the cyclazocine stimulus in all monkeys. UM 
979-cyclazocine combinations had extremely variable 
effects on response rate. In general, UM 979 doses of 
0.03-0.32mg/kg blocked cyclazocine's rate-decreasing 
effects in individual monkeys. The combination of cycla- 
zocine and higher UM 979 doses abolished responding in 
two monkeys. 
Only naltrexone was tested in combination with the 
lowest dose of nalorphine (0.32 mg/kg) required to evoke 
EKC-appropriate responses (Fig. 4, right panels). A dose 
of 0.003, 0.03, or 0.32 mg/kg naltrexone was required to 
block the nalorphine stimulus in monkeys 1205, 1204, and 
975, respectively. During tests of nalorphine-naltrexone 
combinations, 0.32 mg/kg nalorphine continued to evoke 
EKC-appropriate responses when tested alone or in 
combination with saline. However, when nalorphine was 
again tested after an interval of several months, it did not 
evoke EKC-appropriate responses at any dose. Therefore, 
tests of nalorphine-UM 979 combinations were not con- 
ducted. 
Naltrexone antagonism of the cyclazocine stimulus was 
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Fig. 4. Effects of graded doses of naltrexone or UM 979 in combination with 0.03 mg/kg cyclazocine (left, middle panels) or 0.32 mg/kg 
nalorphine (right panels) in individual macaques for which 0.01 mg/kg ethylketazocine (EKC) and saline served as discriminative stimuli 
for food-reinforced responses. Upper panel ordinates: number of responses emitted on the EKC-appropriate lever, expressed as a 
percentage of the total session responses. Lowerpanel ordinates: rate of responding during the session, expressed as a percentage of the 
mean response rate during saline training sessions. Abscissae: mg/kg dose of antagonist administered concomitantly with 0.03 mg/kg 
cyclazocine (left, middle panels) or 0.32 mg/kg nalorphine (right panels). Each drug combination data point represents a single 
determination in each subject. Points at CY represent tests after concomitant administration of 0.03 mg/kg cyclazocine and saline; points 
at N represent tests after administration of 0.32 mg/kg nalorphine and saline. Points at C in the upper panels represent the average 
percentage of responses emitted on the EKC-appropriate lever during training sessions that preceded test sessions. Points at C in the lower 
panels present the effects of 0.01 mg/kg EKC on rate of responding during training sessions. The symbol and average response rate 




o z ~  5 0  
~v 0 I I I l 









s 0.01 0.1 
CYCLAZOCINE, MG/KG 
~ 
S 0.01 0,I 
CYCLAZOCINE, MG/KG 
+ NALTREXONE 
0.32 mg/kg [] 
1204 
S 0.01 0.I 
CYCLAZOCINE, MG/KG 
I 
S 0.01 0.1 
CYCLAZOCINE, MG/KG 
Fig. 5. Cyclazocine dose-response curves determined 
alone (0) or in combination with 0.32 mg/kg 
naltrexone ([3) in three macaques for which 
0.01 mg/kg ethylketazocine and saline served as 
discriminative stimuli for food-reinforced responses. 
Abscissae: mg/kg dose of cyclazocine. Average 
response rates (responses/s) for individual monkeys 
during saline training sessions were: 975, 1.90; 
1205, 1.50; 1204, 2.25. Other details as in Fig. 2 
blocked the stimulus but not, in general, the rate-decreas- 
ing effects of high cyclazocine doses. Thus, the ability of 
cyclazocine to overcome the stimulus blockade produced by 
0.32 mg/kg naltrexone was limited by cyclazocine's insen- 
sitivity to naltrexone antagonism of its rate-decreasing 
effects. 
Discussion 
In the present experiment, naltrexone exerted a surmount- 
able antagonism of the stimulus and rate-altering effects of 
EKC. These results extend our previous report that the 
EKC stimulus in rhesus monkeys is sensitive to naltrexone 
antagonism (Hein et al. 1981). Similarly, naloxone com- 
pletely blocks the EKC stimulus in rats (Herling and 
Shannon 1982; Shearman and Herz 1982). As in the present 
experiment, naloxone antagonism of the EKC stimulus in 
rats is surmountable; the EKC dose required for stimulus 
control is increased threefold by 0.1 mg/kg naloxone and 
30-fold by 1.0mg/kg naloxone (Herling and Shannon 
1982). In contrast, naloxone and naltrexone reduce, but do 
not abolish completely the stimulus control exerted by 
ketazocine or EKC in squirrel monkeys trained with 
cyclazocine (Schaefer and Holtzman 1978; Teal and 
Holtzman 1980b). 
The EKC stimulus effects of the mixed agonist-antag- 
onists nalorphine and cyclazocine also were antagonized by 
naltrexone. Antagonism of the mixed agonist-antagonist 
stimuli differed from that of the EKC stimulus in at least 
two respects. First, antagonism of the nalorphine stimulus 
in individual monkeys required a greater range of naltrex- 
one doses than did antagonism of the EKC stimulus. A 
similar range of individual sensitivities to naloxone anta- 
gonism of a nalorphine stimulus in macaques was reported 
by Tang and Code (1983). Second, naltrexone antagonism 
of the cyclazocine stimulus was not surmountable under 
these conditions. Naltrexone did not alter the rate-decreas- 
ing actions of cyclazocine, with the probable result that 
cyclazocine doses high enough to overcome blockade of its 
stimulus properties were incompatible with execution of the 
required responses. 
Numerous studies of the ability of naloxone or 
naltrexone to block the discriminative effects of n mixed 
agonist-antagonists have employed cyclazocine as the 
reference stimulus. Even high doses of the antagonists do 
not prevent the cyclazocine-like stimulus effects of leval- 
lorphan, oxilorphan, or N-allyl-normetazocine in squirrel 
monkeys (Schaefer and Holtzman 1978; Teal and Holtzman 
1980b). The ability of the antagonists to block the 
cyclazocine stimulus itself varies across experimental con- 
ditions. In contrast to the effectiveness of naltrexone and 
naloxone as antagonists of a cyclazocine stimulus in 
monkeys (Schaefer and Holtzman 1978; Teal and Holtzman 
1980b, c), the antagonists generally do not completely 
block a cyclazocine stimulus in rats (Hirschhorn 1977; 
Rosecrans et al. 1978; Teal and Holtzman 1980a). For 
example, in rats trained to discriminate 0.3 or 1.0 mg/kg 
cyclazocine and saline, no naltrexone dose, up to 30 mg/kg, 
completely antagonizes the cyclazocine stimulus (Teal and 
Holtzman 1980a). However, naltrexone doses of 
0.3-3.0 mg/kg do antagonize completely the cyclazocine 
stimulus in rats trained to discriminate among 0.3 mg/kg 
cyclazocine, 1.0 mg/kg morphine, and saline (White and 
Holtzman 1981). The specific factors underlying these 
disparate results are unclear. 
In addition to antagonizing the stimulus effects of x 
opioids, naltrexone antagonized the rate-decreasing effects 
of EKC and, to a lesser extent, of cyclazocine. The 
naltrexone doses required to block the rate-altering effects 
of EKC were relatively high, however. Although available 
data do not allow direct comparisons of naltrexone 
antagonism of the rate-decreasing effects of EKC and # 
agonists in macaques, comparisons with experiments in 
squirrel monkeys suggest that 10-100-fold higher doses of 
naltrexone were needed to produce a 10-fold shift in the 
EKC dose-response curve in the present study than are 
needed to produce a similar shift in dose-response curves 
for the prototypic # agonist morphine (Goldberg et al. 
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1981). Thus, the present results are consistent with other 
evidence that the rate-decreasing effects of n agonists may 
be less sensitive to antagonism by naloxone or naltrexone 
than are similar effects of ~ agonists (Harris 1980; Leander 
1982; Young and Woods 1982). 
In the present experiment, naltrexone generally re- 
versed the rate-decreasing effects of a low cyclazocine dose 
(0.032 mg/kg), but not those of a higher dose. Under other 
operant behavioral procedures naltrexone and naloxone 
are also relatively ineffective antagonists of the rate-de- 
creasing effects of cyclazocine and other mixed agonist-an- 
tagonists, including nalorphine, pentazocine, and N-al- 
lyl-normetazocine (Downs and Woods 1976; Goldberg,et 
al. 1976; Harris 1980; McMillan et al. 1970; Snell and Harris 
1982). The inability of opioid antagonists to block the 
rate-decreasing effects of these mixed agonist-antagonist 
opioids may suggest that such effects reflect antagonist or 
even nonopioid actions. 
Finally, the present experiments extend a previous 
report that the EKC stimulus is susceptible to antagonists 
with benzomorphan structures. UM 979 exerted a sur- 
mountable antagonism of the stimulus and rate-altering 
effects of EKC and blocked the EKC-like stimulus effects 
of cyclazocine. The diethyl analogue of UM 979, MR 2266, 
also blocks the EKC stimulus in rats (Shearman and Herz 
1982). Previous workers have suggested that MR 2266 is a 
more selective antagonist of x opioids than is naloxone 
(Roemer et al. 1980). For example, in rats, MR 2266 is 
twice as potent as naloxone as an antagonist of a 0.32-mg/kg 
EKC stimulus, but is 1.8-fold less potent than naloxone as 
an antagonist of a 0.04-mg/kg fentanyl stimulus (Shearman 
and Herz 1982). This apparently selective effect was not 
exerted, however, by the particular benzomorphan and 
oxymorphone antagonists used in the present study. UM 
979 was slightly less potent than naltrexone in blocking the 
EKC and cyclazocine stimuli. Additionally, the lowest 
effective doses of UM 979 and naltrexone required similar 
increases in EKC dose to surmount their antagonism of the 
EKC stimulus, while at the highest doses tested, naltrexone 
required a greater increase in EKC dose to surmount its 
blockade than did UM 979, 
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